Wang, Tingting http://orcid.org/0000-0002-6649-3114
Gnanaprakasam, J. N. Rashida
Chen, Xuyong
Kang, Siwen http://orcid.org/0000-0002-3851-8812
Xu, Xuequn
Sun, Hua
Liu, Lingling
Rodgers, Hayley
Miller, Ethan
Cassel, Teresa A.
Sun, Qiushi
Vicente-Muñoz, Sara
Warmoes, Marc O.
Lin, Penghui
Piedra-Quintero, Zayda Lizbeth
Guerau-de-Arellano, Mireia
Cassady, Kevin A.
Zheng, Song Guo
Yang, Jun http://orcid.org/0000-0002-0770-9659
Lane, Andrew N. http://orcid.org/0000-0003-1121-5106
Song, Xiaotong http://orcid.org/0000-0002-2907-2898
Fan, Teresa W.-M. http://orcid.org/0000-0002-7292-8938
Wang, Ruoning http://orcid.org/0000-0001-9798-8032
Funding for this research was provided by:
American Cancer Society (130421-RSG-17-071-01-TBG, 128436-RSG-15-180-01-LIB)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA229739, 1P01CA163223-01A1, 1P01CA163223-01A1, 1UO1CA232488-01, 1R21CA227926-01A1)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (1U24DK097215-01A1, 1U24DK097215-01A1)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (1R01AI114581)
V Foundation for Cancer Research (V2014-001)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 10 September 2019
Accepted: 30 April 2020
First Online: 15 June 2020
Competing interests
: X.S. currently is the CEO of Icell Kealex Therapeutics, which is a pharmaceutical start-up company that actively develops the neutralization escape variant of oncolytic virus and integrated T-cell-based immunotherapy. All other authors declare no competing interests.